Randomized placebo‐controlled trial of losartan for pediatric NAFLD

BACKGROUND AND AIMS: To date, no pharmacotherapy exists for pediatric NAFLD. Losartan, an angiotensin II receptor blocker, has been proposed as a treatment due to its antifibrotic effects. APPROACH AND RESULTS: The Nonalcoholic Steatohepatitis Clinical Research Network conducted a multicenter, doubl...

Descripción completa

Detalles Bibliográficos
Autores principales: Vos, Miriam B., Van Natta, Mark L., Blondet, Niviann M., Dasarathy, Srinivasan, Fishbein, Mark, Hertel, Paula, Jain, Ajay K., Karpen, Saul J., Lavine, Joel E., Mohammad, Saeed, Miriel, Laura A., Molleston, Jean P., Mouzaki, Marialena, Sanyal, Arun, Sharkey, Emily P., Schwimmer, Jeffrey B., Tonascia, James, Wilson, Laura A., Xanthakos, Stavra A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288975/
https://www.ncbi.nlm.nih.gov/pubmed/35133671
http://dx.doi.org/10.1002/hep.32403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288975/
https://www.ncbi.nlm.nih.gov/pubmed/35133671
http://dx.doi.org/10.1002/hep.32403

Ejemplares similares